Atezolizumab plus bevacizumab combination for untreated metastatic kidney cancer

Results from this phase III trial of atezolizumab plus bevacizumab versus sunitinib for patients with untreated renal cell carcinoma (IMmotion 151) were published in The Lancet last month. The study involved 915 patients, of which 40% were positive for PD-L1 biomarkers. In the PD-L1 positive group of patients, the combination of atezolizumab plus bevacizumab was […]

read more

Safety and tolerability of atezolizumab plus bevacizumab combination for untreated metastatic kidney cancer

The combined safety results of two studies with the atezolizumab plus bevacizumab combination were presented at the European Society of Medical Oncology (ESMO) Congress in Munich, Germany last week. The phase 2 IMmotion 150 clinical trial compared the efficacy of the atezolizumab plus bevacizumab combination with atezolizumab alone and sunitinib alone, and then allowed for crossover to […]

read more

ESMO 2018: Cabozantinib in combination with atezolizumab in metastatic kidney cancer

The following video interview from Practice Update discusses the promising results from the phase 1b trial of cabozantinib in combination with atezolizumab for metastatic renal cell carcinoma (RCC), the results of which were presented at the European Society of Medical Oncology (ESMO) conference in Munich, Germany last week. Watch the video interview from Practice Update here

read more

ESMO 2018: Cabozantinib/atezolizumab combination shows encouraging clinical activity for untreated advanced RCC

Results from the phase 1b COSMIC-021 study of cabozantinib in combination with atezolizumab in people with previously untreated advanced renal cell carcinoma (RCC) were presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich over the weekend. This dose-escalation study primarily looked at the safety of the cabozantinib + atezolizumab combination in […]

read more

Patient-reported outcomes for atezolizumab plus bevacizumab combination

Patient-reported outcomes from the phase 3 IMmotion151 study, which assessed the atezolizumab plus bevacizumab combination versus sunitinib in metastatic renal cell carcinoma (RCC) patients, were presented at the 2018 American Society of Clinical Oncology (ASCO) annual meeting in Chicago this week. In the IMmotion151 clinical trial, the combination of atezolizumab plus bevacizumab improved progression-free survival […]

read more

Atezolizumab plus bevacizumab combination is positive for untreated metastatic kidney cancer

The combination of immunotherapy atezolizumab (Tecentriq) with targeted therapy bevacizumab (Avastin) has been shown to delay the growth of metastatic renal cell carcinoma (mRCC) in a phase III clinical trial called IMmotion151. In the trial, the combination delayed cancer growth by about 3 months compared to standard treatment with sunitinib, another targeted therapy. The benefit […]

read more

Positive interim results for atezolizumab plus bevacizumab combination in advanced RCC

Interim results from the phase III IMmotion151 study to assess a combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) for advanced or metastatic renal cell carcinoma (RCC) have been reported to have improved progression-free survival (PFS), compared to sunitinib (Sutent) as a first-line treatment. The researchers said that the combination provided a statistically significant and clinically […]

read more

Combination treatment with atezolizumab plus bevacizumab improves progression-free survival

Results from the IMmotion150 phase II clinical trial showed that a combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) improved progression-free survival (PFS) in patients with untreated metastatic renal cell carcinoma (mRCC) compared with standard treatment with sunitinib (Sutent). These results were presented at the 2017 European Society of Medical Oncology (ESMO) conference in Madrid, Spain […]

read more

Atezolizumab plus bevacizumab combination show promise for first-line kidney cancer treatment

Results from the IMmotion150 Phase 2 clinical trial, a global, multicentre, randomised study to compare the safety and effectiveness of atezolizumab (Tecentriq) in combination with bevacizumab (Avastin) with atezolizumab alone and sunitinib (Sutent) alone, were presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in Orlando USA last week. The results showed […]

read more
Showing 11 to 19 of 19 results
  TOP